Experimental cell therapy takes on lupus in early trial

NCT ID NCT07314567

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called ACE1831 for people with lupus that has not responded to standard therapies. ACE1831 is made from healthy donor immune cells and is given after a short course of chemotherapy. The study will enroll 22 adults aged 18 to 60 with moderate to severe active lupus to see if the treatment is safe and shows signs of helping control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACE1831 (a type of immune cell therapy made from healthy donors' cells, given with chemotherapy)
What this could lead to: If this works, it could point toward a new treatment option for people with lupus that hasn't responded to other therapies.
What could go wrong: This is a very early, small study with only 22 participants, so results may not apply to everyone. The treatment involves chemotherapy and carries risks like infections or side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEM LUPUS ERYTHEMATOSUS(SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEM LUPUS ERYTHEMATOSUS(SLE)

Contacts and locations

Locations

Tongji Hospital

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.